1783 — Maxigen Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeSmall CapFalling Star

Annual cashflow statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	72.8	76.7	97.5	166	193
Depreciation
Amortisation
Non-Cash Items	-1.25	-0.622	5.19	13.8	-18
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-9.62	-34.9	-18	59.2	-31.5
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	94.4	74.4	118	268	171
Capital Expenditures	-23.7	-11.3	-15.4	-12	-19
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	66.4	150	12.7	22.4	-471
Sale of Fixed Assets
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	42.6	139	-2.77	10.4	-490
Financing Cash Flow Items	—	-215	0.101	-0.101	0
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-54.4	-271	189	-1.05	-41.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	82.8	-57.9	304	278	-360